Low-Grade Glioma - Epidemiology Forecast-2032

This ‘Low-grade glioma- Epidemiology Forecast-2032' report delivers an in-depth understanding of the disease, historical and forecasted epidemiology in the United States, EU-5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Geography Covered

• The United States
• EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Low-grade glioma Disease Understanding

Low-grade glioma Overview

Low-grade glioma (LGGs) are a diverse group of primary brain tumors that often arise in young, otherwise healthy patients and generally have an indolent course with longer-term survival in comparison with high-grade glioma. Moreover, in this type of brain tumor with a relatively good prognosis and prolonged survival, the potential benefits of treatment must be carefully weighed against potential treatment-related risks.Low-grade astrocytic tumors include diffuse astrocytoma, pilomyxoid astrocytoma, and pleomorphic xanthoastrocytoma (WHO grade II), as well as subependymal giant cell astrocytoma (SEGA) and pilocytic astrocytoma (WHO grade I tumors).

IDH1 and IDH2 are the most commonly mutated genes in low grade glioma, with mutations estimated to occur in > 70% of cases. BRAF V600E point mutations are occasionally observed in pilocytic astrocytoma; the mutations are also observed in nonpilocytic pediatric low-grade glioma, including ganglioglioma, desmoplastic infantile ganglioglioma, and approximately two-thirds of pleomorphic xanthoastrocytomas.

The symptoms include seizure loss of time, feeling of deja vu or jamais vu, trouble speaking and understanding other people speaking, episodes of confusion, numbness or weakness and vision problems.

Low-grade glioma Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total incident population of primary brain cancer, total incident population of low-grade glioma, Grade-specific , age specific ,type-specific cases of low-grade glioma the further segmentation done by low-grade glioma cases based on molecular alterations and enhancing and non-enhancing low-grade glioma in the 7MM market covering the United States, EU-5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2019 to 2032.

Key Findings

This section provides glimpse of the LGG epidemiology in the 7MM

Country Wise- Low-grade glioma Epidemiology

• The epidemiology segment also provides the LGG epidemiology data and findings across the United States, EU-5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
• The total incident population of LGG in the 7MM comprised of 9,078 cases in 2021 and are projected to increase during the forecast period.
• The total incident population of glioma in the United States is 3,654 in 2021.
• The United States contributed to the largest incident population of LGG, accounting for ~ 40% of the 7MM in 2021.
• In the EU-5 countries, the diagnosed prevalence of LGG was found to be maximum in Germany followed by France. While, the least number of cases were found in Spain, in 2021.
• In Japan, the total incident population of LGG is 814 in 2021 and is anticipated to rise during the forecast period.
• In 2021, 2,958 patients accounted for IDH mutation, and 251 accounted for BRAF V600E cases in the United States.
• In 2021, the Grade II non-enhancing LGGs accounted for 1,819 cases in the United States.
• In the United States, there were number of Grade 2 glioma cases are higher than the Grade I cases in 2021.
• In the US, based on age, the maximum cases are in the age group of < 18 years i.e. 1,253 followed by 18-44 years, 45-59 years, 60-74 years, and least in ≥75 years in 2021.
• Based on the molecular alterations the incident population of LGG is segmented into diffuse astrocytoma, oligodendroglioma, oligoastrocytic tumors, pilocytic astrocytoma, ependymal tumors, and unique astrocytoma variants. In 2021, the diffuse astrocytoma and oligodendroglioma in the United States accounted for 1,161 and 689, respectively

Scope of the Report

• The report covers the descriptive overview of LGG, explaining its causes, signs and symptoms, pathogenesis and diagnosis.
• Comprehensive insight has been provided into the LGG epidemiology and treatment.
• The report provides insight about the historical and forecasted patient pool of Huntington's disease in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• As per the analysis, LGG can be divided into two grades, namely,Grade I and Grade II gliomas.
• The report also encompasses other major segments, i.e., age-specific, type-specific cases of low-grade glioma, incident pool based on molecular alterations, and enhancing/non-enhancing.

Report Highlights

• Eleven Years Forecast
• 7MM Coverage
• Total Incidance cases of LGG
• Age-specific cases of LGG

LGG Report Insights

• Patient Population
• Eleven Years Forecast
• 7MM Coverage
• LGG Epidemiology Segmentation

Key Questions Answered

• What is the disease risk, burden and unmet needs of LGG?
• What is the historical LGG patient pool in the United States, EU-5 (Germany, France, Italy, Spain, and the UK) and Japan?
• What would be the forecasted patient pool of LGG at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to LGG?
• Out of the above-mentioned countries, which country would have the highest incident population of LGG during the study period (2019-2032)?
• At what CAGR the population is expected to grow across the 7MM during the study period (2019-2032)?

Reasons to Buy

• The report will help in developing business strategies by understanding trends shaping and driving the LGG.
• Quantify patient populations in the global LGG market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the best opportunities for LGG in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
• The LGG Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources.